Clinical Development - The company is developing three clinical-stage product candidates targeting autoimmune and inflammatory diseases, with a focus on significant unmet medical needs [22]. - Tibulizumab is currently undergoing two global Phase 2 clinical trials, with TibuSHIELD evaluating approximately 225 participants and TibuSURE evaluating approximately 80 participants [57][60]. - The primary endpoint for TibuSHIELD is the percent change from baseline in total abscess and inflammatory nodule count at Week 16, with topline results expected in Q4 2026 [58]. - The primary endpoint for TibuSURE is the modified Rodnan Skin Score at Week 24, with topline results expected in the first half of 2027 [61]. - Crebankitug is designed to inhibit signaling mediated by both IL-7 and TSLP, targeting the interleukin-7 receptor alpha chain [63]. - The ongoing clinical trials are designed to assess safety, tolerability, and efficacy, with a focus on addressing inflammatory and B cell-associated components in disease pathogenesis [55]. - Crebankitug was administered to 93 participants in Phase 1/1b clinical trials, demonstrating biologic activity consistent with IL-7Rα blockade, including reductions in effector and memory T cell populations [69]. - The Phase 2 clinical trial for torudokimab in moderate-to-severe atopic dermatitis was terminated early due to lack of efficacy, although safety findings did not contribute to the termination [78]. - The company has multiple product candidates in development targeting various pathways for conditions such as Hidradenitis Suppurativa and Systemic Sclerosis [183][185]. Financial Obligations and Agreements - The company has made a total of $5.8 million upfront payment and issued 1,000,000 Class A Ordinary Shares valued at $7.8 million to Lilly under the 2023 license agreement for tibulizumab [92]. - The company is obligated to make up to $155.0 million in development milestone payments and up to $440.0 million in sales milestone payments to Lilly based on net sales of products developed from tibulizumab [94]. - Under the Pfizer Agreement, the company acquired a license for crebankitug for $5.0 million in cash and 2,702,083 shares, representing a 20% interest in the company [97]. - The company is obligated to make up to $70.0 million in development and regulatory milestone payments and up to $525.0 million in sales milestone payments to Pfizer based on net sales of products developed from crebankitug [98]. - The first $1.0 million development milestone under the Pfizer Agreement was recorded as a component of research and development expenses during the year ended December 31, 2023 [99]. - The Athanor Agreement, effective December 29, 2025, includes an upfront fee of $7.3 million and a one-time milestone payment of $25 million upon certain events, along with a 2% royalty on net sales [107]. Regulatory Environment - The company is subject to FDA regulations for drug products, requiring compliance with various laws and regulations throughout the product development and approval process [108]. - Biologics must undergo a biologics license application (BLA) process, which includes preclinical studies, clinical trials, and FDA review before marketing approval [109]. - The FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of a product candidate, although a single trial may suffice in certain cases [114]. - The FDA's PDUFA review goal is to review 90% of priority BLA applications within six months and 90% of standard applications within ten months of filing [118]. - Post-approval requirements include rigorous compliance with cGMP regulations, record keeping, and reporting of adverse experiences [124]. - The centralized procedure allows for a single marketing authorization (MA) valid across the European Economic Area (EEA), which includes 27 EU Member States plus Iceland, Liechtenstein, and Norway [131]. - The maximum evaluation timeframe for an MA application under the centralized procedure is 210 days, which can be reduced to 150 days for accelerated assessments in cases of unmet medical needs [133]. - Conditional marketing authorizations can be granted when not all safety and efficacy data are available, valid for one year and renewable annually until conditions are fulfilled [139]. - The Clinical Trials Regulation (CTR) aims to harmonize clinical trial authorizations and improve transparency, effective since January 31, 2022 [146]. Market and Competitive Landscape - The immunology market is characterized by strong competition, with numerous entities developing diverse therapeutic modalities for autoimmune diseases [174]. - Established companies may have competitive advantages due to greater resources and experience in securing reimbursement and regulatory approvals [176]. - Competition may arise from off-label use of products approved for other indications and alternative therapies available through clinical trials or expanded access [179]. Financial Performance and Projections - The company incurred a net loss of $68.7 million for the fiscal year ended December 31, 2025, and expects to continue incurring significant losses in the foreseeable future [207]. - The company has not generated any revenue from the ZB Assets and may never achieve profitability [204]. - The company is a clinical-stage entity with a limited operating history and has not completed any clinical trials or taken a product through to commercialization [199]. - The company plans to fund its operations through existing proceeds, future equity sales, debt, and potential collaborations [208]. - Company may face delays, reductions, or suspensions in research and development programs if unable to raise additional capital, negatively impacting business and financial condition [209]. - Anticipated expenses related to ongoing activities, particularly clinical trials for ZB Assets, are expected to increase, with potential costs exceeding current estimates due to regulatory requirements [210]. - Company lacks committed external funding sources, and failure to secure additional financing may restrict operational activities and dilute shareholder interests [211]. - Development plans for ZB Assets may be limited due to financial constraints, with current Phase 2 trials prioritized while other indications remain uninitiated [212]. - Allocation of resources toward specific indications may not yield viable commercial products, potentially diverting attention from more profitable opportunities [213]. - Future licensing of additional assets may require further capital expenditure, with no assurance of generating sufficient cash flow from operations [214]. Operational Challenges - Participant enrollment is critical for timely clinical trials, with various factors potentially delaying recruitment and increasing costs [215]. - Delays in participant enrollment or retention could compromise data integrity, affecting the ability to obtain regulatory approvals [218]. - Inability to enroll sufficient patients may lead to significant delays in clinical trials and increased development costs, potentially requiring abandonment of trials [219].

FedEx Reports Strong Third Quarter Results Raises Full-year Fiscal 2026 Earnings Outlook On Track to Spin Off FedEx Freight on June 1, 2026 MEMPHIS, Tenn., March 19, 2026 ... FedEx Corp. (NYSE: FDX) today reported the following consolidated results for the third quarter ended February 28 (adjusted measures exclude the items listed below): | | Fiscal 2026 | | Fiscal 2025 | | | --- | --- | --- | --- | --- | | | As Reported | Adjusted | As Reported | Adjusted | | | (GAAP) | (non-GAAP) | (GAAP) | (non-GAAP) | | ...

Financial Guidance - electroCore, Inc. provided preliminary financial guidance for the three and 12 months ended December 31, 2025[4] - The financial results are based on unaudited information and management estimates, subject to change[6] - The company cautioned that actual results may differ materially from the preliminary estimates provided[8] - Upcoming presentations will include these preliminary financial estimates for investor and analyst discussions[5] Audit and Review - The independent registered public accounting firm has not conducted an audit or review of these preliminary results[6] - The financial information is not deemed "filed" under the Securities Exchange Act of 1934[7] Risk Factors - Investors are advised to refer to the "Risk Factors" section of the Company's Annual Report for potential discrepancies in actual results[8] Forward-Looking Statements - The company has no obligation to publicly release updates on forward-looking statements unless required by law[8] Documentation - The press release and investor presentation are filed as Exhibits 99.1 and 99.2, respectively[11] - The report was signed by Joshua S. Lev, Chief Financial Officer, on January 20, 2026[15]

Employment and Workforce - In 2025, Kohl's employed an average of approximately 84,000 associates, including about 29,000 full-time and 55,000 part-time associates[19]. - The company maintains a commitment to competitive compensation, offering a 100% match in the 401(k) Savings Plan up to 5% of pay after one year of employment[24]. - Kohl's has a strong focus on employee wellness, providing various mental well-being and personal growth benefits, including counseling sessions and proactive coaching[25]. - The company emphasizes a culture of inclusion and belonging, with over 8,500 members in its Business Resource Groups[22]. - Kohl's is committed to ethical standards and requires annual ethics training for all associates[28]. Financial Commitments and Risks - The company has no significant long-term purchase commitments with any suppliers, and no vendor accounted for more than 10% of net purchases in 2025[31]. - Kohl's is subject to interest rate risk from its $1.5 billion revolving credit facility, which bears interest at a variable rate based on SOFR plus the applicable margin[211]. - The remaining $425 million of notes outstanding issued in March 2021 include coupon rate step-ups if the long-term debt is downgraded below a BBB- credit rating, which has occurred in 2023, 2024, and 2025[210]. Business Operations - The retail business is subject to seasonal influences, with sales typically higher during back-to-school and holiday seasons[32]. - Kohl's has over 200 registered trademarks, which are considered valuable to the business[33].

Revenue Performance - Tenon Medical, Inc. reported unaudited revenue for Q4 2025 of $1.45 to $1.48 million, representing a 90% year-over-year increase compared to Q4 2024[4] - For the fiscal year 2025, the company reported unaudited revenue of $3.91 to $3.94 million, reflecting a 20% year-over-year increase compared to fiscal year 2024[4] Future Financial Reporting - The company plans to release detailed financial results for Q4 and full year 2025 on March 19, 2026, after market close[5]

Offering Details - Zura Bio Limited is offering 18,200,000 Class A Ordinary Shares and pre-funded warrants to purchase up to 1,800,000 Class A Ordinary Shares[1] - The offering includes an option for underwriters to purchase an additional 3,000,000 Ordinary Shares[1] - The purchase price for the Pre-Funded Warrants is set at $6.249 per warrant, with a withholding of $0.375 per warrant for offsets[83] - The initial public offering price per Ordinary Share is set at $6.25, while the price per Pre-Funded Warrant is $6.249[160] - The purchase price per Ordinary Share for the Underwriters is $5.875, which is $0.375 less than the initial public offering price[161] - The company has granted an option to the Underwriters to purchase up to an additional 3,000,000 Ordinary Shares[164] - The total number of shares allocated to Leerink Partners LLC is 7,280,000, while Piper Sandler & Co. and Cantor Fitzgerald & Co. received 5,278,000 and 4,550,000 shares respectively[162] - The total number of Pre-Funded Warrants allocated is 1,800,000, with 720,000 going to Leerink Partners LLC[162] Regulatory Compliance - The company has filed a shelf registration statement on Form S-3, which was declared effective on September 17, 2024[2] - The Ordinary Shares are registered under Section 12(b) of the 1934 Act and listed on the Nasdaq Stock Market[19] - The company has complied with the reporting requirements of Section 13 or Section 15(d) of the 1934 Act[19] - The company has filed a Notification of Listing of Additional Shares with Nasdaq regarding the Securities[19] - The interactive data included in the Registration Statement has been prepared in accordance with the Commission's rules and guidelines[17] - The Company is not classified as an "investment company" under the Investment Company Act of 1940[28] - There are no registration rights for any equity or debt securities of the Company that would affect the current offering[36] - The Company is in compliance with all material aspects of the Employee Retirement Income Security Act (ERISA) and has no reportable events expected regarding its employee benefit plans[52] - The Company is compliant with the Sarbanes-Oxley Act of 2002, with no known failures in compliance by its directors or officers[53] - The Company and its Subsidiaries are in compliance with all applicable laws and regulations, including those from the FDA and EMA, with no material adverse effects expected[61] - The Company has filed all required documents with the Commission pursuant to the 1934 Act within the specified time periods[94] Financial Condition - There has been no material adverse change in the Company's business or financial condition since the last reporting date[35] - No material liabilities or obligations have been incurred by the Company that would adversely affect its financial condition[35] - The financial statements of the Company and its Subsidiaries present a fair consolidated financial position and results of operations in compliance with GAAP[37] - The Company has filed all required tax returns and paid all taxes due, with no material tax deficiencies asserted against it[42] - The Company has no material outstanding loans or related party transactions that have not been disclosed[65] - The Underwriters have the right to terminate the Agreement if there is a material adverse change in the Company's financial condition or market conditions[134] Corporate Structure and Governance - The Company is duly incorporated and in good standing under the laws of the Cayman Islands, with full corporate power to conduct its business[21] - Each Subsidiary is validly existing and in good standing under its jurisdiction, with all issued share capital fully paid and owned by the Company[23] - The Company has authorized and outstanding capitalization as described in the Registration Statement, with all shares validly issued and free of encumbrances[24] - The Securities to be purchased by the Underwriters have been duly authorized and will be validly issued and fully paid upon delivery[25] - The Company has established effective internal accounting controls and disclosure controls, with no material weaknesses reported[48] - The Company has good and marketable title to all material properties, free of encumbrances that would affect their value[45] Legal and Insurance Matters - There are no pending legal proceedings that could materially affect the Company's ability to perform its obligations[38] - The Company and its Subsidiaries maintain adequate insurance coverage for their businesses, including clinical trial liability claims[44] - There are no ongoing legal proceedings that could materially affect the Company or its Subsidiaries[64] - The Company has not received any adverse findings or notices from governmental authorities regarding compliance with applicable laws[61] Intellectual Property - The Company owns or possesses rights to all necessary intellectual property for its business operations, with no known challenges to its rights[59] - The Company's patents have been duly maintained and are in full force, with no adjudged invalid or unenforceable patents since in-licensing[59] - The Company has taken reasonable steps to secure its interests in intellectual property and protect confidential information[59] - The Company is not bound by any agreements that materially restrict its use of intellectual property[59] Operational Compliance - The Company has conducted all non-clinical studies and clinical trials in accordance with applicable laws and protocols, with no material serious adverse events reported[62][63] - The Company has maintained compliance with privacy and data protection laws, with no significant security breaches reported in the past three years[68] - The Company has established disaster recovery and security plans for its IT assets, consistent with industry standards[68] - The Company is in compliance with all applicable health care laws and has not received any claims or actions alleging violations[73] Agreement and Indemnity - The Company agrees to indemnify Underwriters against any losses arising from untrue statements or omissions in the Registration Statement[120] - The Company must provide additional documents and opinions as required by the Underwriters to ensure compliance with the issuance and sale of Securities[118] - The Company is obligated to provide a Bring-down Comfort Letter if requested by the Underwriters[116] - The Underwriters may seek contribution from the Company for any losses incurred due to untrue statements or omissions[126] - The Company must notify the Underwriters of any actions commenced against it for which indemnity may be sought[123] - The Company must ensure that all proceedings related to the issuance and sale of Securities are satisfactory to the Underwriters[118] Miscellaneous - The agreement includes provisions for default by Underwriters, allowing for arrangements to be made within 24 hours if any Underwriter fails to purchase the Securities[137] - The agreement is governed by the laws of the State of New York, and any legal proceedings must be instituted in specified courts in New York[148][149] - The time of the agreement is of the essence, with specified times referring to New York City time[150]

Financial Performance - Assembly Biosciences reported a net loss of $6.1 million, or $0.55 per share, for the year ended December 31, 2025, compared to a net loss of $40.2 million, or $6.69 per share, in 2024[11]. - Revenue from collaborative research with Gilead was $72.3 million for the year ended December 31, 2025, up from $28.5 million in 2024, reflecting a significant increase in collaboration funding[8]. - Cash, cash equivalents, and marketable securities totaled $248.1 million as of December 31, 2025, compared to $232.6 million as of September 30, 2025, and $112.1 million as of December 31, 2024[8]. - Total assets increased to $257.6 million as of December 31, 2025, compared to $119.2 million in 2024[15]. Expenses - Research and development expenses increased to $64.8 million for the year ended December 31, 2025, from $55.9 million in 2024, driven by spending on the helicase-primase inhibitor program[11]. - General and administrative expenses rose to $19.6 million for the year ended December 31, 2025, compared to $18.0 million in 2024, primarily due to higher professional fees and stock-based compensation[11]. Licensing and Collaborations - The company successfully licensed its helicase-primase inhibitor program, including candidates ABI-5366 and ABI-1179, to Gilead, receiving a net $35 million option fee[5]. - The company is positioned to opt into a 40% U.S. cost-profit share for the herpesvirus HPI program by mid-2026, pending Gilead's development plan and budget[8]. Clinical Development - Assembly Biosciences anticipates initiating a Phase 2 clinical study for ABI-6250 by the end of 2026, targeting chronic hepatitis delta virus[8]. - The company completed dosing and follow-up for all participants in Phase 1a/b studies for ABI-5366 and ABI-1179[5].

Financial Performance - For the year ended December 31, 2025, Curis reported a net loss of $7.6 million, or $0.58 per share, compared to a net loss of $43.4 million, or $6.88 per share in 2024[9]. - Revenues for the year ended December 31, 2025, were $9.4 million, down from $10.9 million in 2024, with fourth-quarter revenues of $1.1 million compared to $3.3 million in the same period in 2024[10]. - Revenues for the three months ended December 31, 2025, were $1,138 million, a decrease from $3,345 million in the same period of 2024[26]. - The company reported a net loss per common share of $0.58 for the twelve months ended December 31, 2025, improving from a loss of $6.88 in 2024[26]. - Total operating expenses for the twelve months ended December 31, 2025, were $42,345 million, down from $55,450 million in 2024[26]. - Net income for the three months ended December 31, 2025, was $19,356 million, compared to a net loss of $9,618 million in the same period of 2024[26]. Expenses - Research and development expenses decreased to $28.3 million for the year ended December 31, 2025, from $38.6 million in 2024, with fourth-quarter expenses of $5.8 million compared to $9.0 million in 2024[13]. - General and administrative expenses were $14.0 million for the year ended December 31, 2025, down from $16.8 million in 2024, with fourth-quarter expenses of $2.9 million compared to $3.4 million in 2024[14]. Assets and Liabilities - Total assets decreased to $19,966 million as of December 31, 2025, from $41,265 million in 2024[28]. - Total liabilities were $14,504 million as of December 31, 2025, down from $47,263 million in 2024[28]. - Cash and cash equivalents decreased to $5,061 million as of December 31, 2025, from $19,997 million in 2024[28]. - Accounts payable and accrued liabilities increased to $12,886 million as of December 31, 2025, compared to $10,135 million in 2024[28]. - The company maintained goodwill at $8,982 million for both December 31, 2025, and 2024[28]. Cash Position and Financing - As of December 31, 2025, Curis had cash and cash equivalents totaling $5.1 million, with approximately 12.9 million shares of common stock outstanding[17]. - Curis expects its cash runway, including initial gross proceeds of $20.2 million from the January 2026 PIPE Financing, to support operations into the second half of 2027[18]. Clinical Development - Curis initiated a Phase 2 clinical study of emavusertib in combination with zanubrutinib for Chronic Lymphocytic Leukemia (CLL) patients[4]. - The company continues to enroll patients in the TakeAim Lymphoma study, which aims to support filings for accelerated approval in Primary CNS Lymphoma (PCNSL) in the US and Europe[5]. - Emavusertib has received orphan drug designation from both the FDA and EMA for the treatment of PCNSL[5]. Non-Cash Gains - Curis recognized a non-cash gain of $27.2 million in the fourth quarter of 2025 from the release of liability related to the sale of future royalties associated with the sale of Erivedge[15]. - The company reported a gain on the release of liability related to the sale of future royalties of $27,189 million for the twelve months ended December 31, 2025[26].

Financial Performance - Net income for the year ended December 31, 2025 improved to $1,273,000 or $0.06 per diluted share compared to a net loss of $918,000 or ($0.05) per diluted share in the same period of 2024[8] - Total revenue for the full year ended December 31, 2025 increased 13% to $22,666,000 compared to $19,997,000 in the same period of 2024[6] - Adjusted EBITDA improved to $2,566,000 for the year ended December 31, 2025 compared to $520,000 for the same period of 2024[8] - Net income for the fourth quarter improved significantly to $1,552,000 or $0.08 per diluted share compared to net income of $488,000 or $0.03 per diluted share for the same period in 2024[4] - Net income for 2025 was $1,273,000, a significant improvement from a net loss of $918,000 in 2024[19] - Adjusted EBITDA for 2025 reached $2,566,000, compared to $520,000 in 2024, indicating strong operational performance[19] Revenue Growth - Fourth quarter total revenue grew 12% to a record $6,635,000 compared to $5,936,000 in the same period of 2024[1] - Fourth quarter SaaS revenue grew 12% and totaled $6,620,000 compared to $5,913,000 in the same period of 2024[1] - Revenues increased to $22,666,000 in 2025, up from $19,997,000 in 2024, reflecting a growth of approximately 8.3%[22] - Adjusted gross profit for 2025 was $20,999,000, compared to $18,347,000 in 2024, representing an increase of about 9%[22] Operating Expenses - Operating expenses for the year ended December 31, 2025 were $19,414,000 compared to $19,334,000 for the same period of 2024[7] - Operating expenses for the fourth quarter of 2025 decreased by 7% to $4,571,000 compared to $4,928,000 for the same period of 2024[3] - Stock-based compensation expense was $777,000 in 2025, down from $876,000 in 2024[19] Cash Position - Cash balance totaled $9,650,000 at year end December 31, 2025, an increase from $4,666,000 in 2024[9] - Cash provided by operating activities was $4,541,000 in 2025, a turnaround from cash used of $2,694,000 in 2024[16] - Cash and cash equivalents at the end of 2025 totaled $9,650,000, up from $4,666,000 at the end of 2024[16] Accounts Receivable - The company reported a decrease in accounts receivable by $1,165,000 in 2025, compared to an increase of $219,000 in 2024[16] Market Reach - The company is processing identity transactions for nearly half of the adult population in the U.S. and Canada annually, showcasing its market reach[23]

Financial Position - As of December 31, 2025, SELLAS Life Sciences Group, Inc. estimates its unaudited cash and cash equivalents position at $71.8 million[4] - The company received approximately $26.5 million in proceeds from the exercise of common stock warrants after December 31, 2025[5] Share Information - As of January 7, 2026, the company had 170,282,026 shares of common stock outstanding[6]